Cape Investment Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Cape Investment Advisory’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-350	Closed	-$1.71K	–	1333
2025 Q3	$1.71K	Hold	350	–	–	﹤0.01%	698
2025 Q2	$1.77K	Hold	350	–	–	﹤0.01%	963
2025 Q1	$1.85K	Sell	350 -154	-31%	-$1.12K	﹤0.01%	904
2024 Q4	$3.41K	Buy	504 +154	+44%	+$1.03K	﹤0.01%	813
2024 Q3	$2.31K	Hold	350	–	–	﹤0.01%	807
2024 Q2	$2.63K	Hold	350	–	–	﹤0.01%	765
2024 Q1	$3.49K	Hold	350	–	–	﹤0.01%	706
2023 Q4	$3.45K	Buy	+350	New	+$2.5K	﹤0.01%	838
2023 Q3	–	Sell	-250	Closed	-$1.87K	–	942
2023 Q2	$1.87K	Hold	250	–	–	﹤0.01%	779
2023 Q1	$1.67K	Buy	+250	New	+$1.98K	﹤0.01%	831

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cape Investment Advisory's RXRX Position: Q4 2025 in Review

Cape Investment Advisory sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 350 shares — an estimated $1.71K sold.

Cape Investment Advisory first reported a position in RXRX in Q1 2023 and held it in 10 quarters. The position peaked at $3.49K in Q1 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Cape Investment Advisory reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Cape Investment Advisory sold 350 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1.71K.
Cape Investment Advisory first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 10 quarters.
Cape Investment Advisory's Recursion Pharmaceuticals position peaked at $3.49K in Q1 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Cape Investment Advisory's 13F filing for Q4 2025, filed 17 Feb 2026.